[go: up one dir, main page]

Georgiadou et al., 2024 - Google Patents

Anemia and tissue hypoxia are major determinants of malarial hypelactatemia

Georgiadou et al., 2024

View PDF
Document ID
2637028451927323515
Author
Georgiadou A
Yoon C
Yu H
Pearson W
Ueno A
Ebmeier S
Larrouy-Maumus G
Cunnington A
Publication year
Publication venue
bioRxiv

External Links

Snippet

Hyperlactatemia, a key marker of severe malaria, is closely linked to increased mortality, though the exact mechanisms remain unclear. It may result from increased lactate production due to tissue hypoxia or reduced lactate clearance from organ dysfunction. This …
Continue reading at www.biorxiv.org (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Similar Documents

Publication Publication Date Title
Sun et al. p53 deacetylation alleviates sepsis-induced acute kidney injury by promoting autophagy
Liu et al. Induction of neutrophil extracellular traps during tissue injury: Involvement of STING and Toll‐like receptor 9 pathways
Fähling et al. Tubular von Hippel-Lindau knockout protects against rhabdomyolysis-induced AKI
Arora et al. The effect of everolimus initiation and calcineurin inhibitor elimination on cardiac allograft vasculopathy in de novo recipients: one‐year results of a Scandinavian randomized trial
Liu et al. Heme mediated STAT3 activation in severe malaria
Moxon et al. Parasite histones are toxic to brain endothelium and link blood barrier breakdown and thrombosis in cerebral malaria
Merezhinskaya et al. Presence and localization of three lactic acid transporters (MCT1,− 2, and− 4) in separated human granulocytes, lymphocytes, and monocytes
Beri et al. Commit, hide and escape: the story of Plasmodium gametocytes
WO2020169819A1 (en) Diagnosis or prognosis of postsurgical adverse events
JP2010525326A5 (en)
Yang et al. Faecalibacterium prausnitzii as a potential Antiatherosclerotic microbe
Dong et al. 5‐Hydroxytryptamine (5‐HT)‐exacerbated DSS‐induced colitis is associated with elevated NADPH oxidase expression in the colon
Usui et al. Stressed out about Plasmodium falciparum gametocytogenesis
Kempaiah et al. Reduced Hsp70 and glutamine in pediatric severe malaria anemia: role of hemozoin in suppressing Hsp70 and NF-κB activation
WO2021158720A1 (en) Disease detection and treatment based on phenylacetyl glutamine levels
Congpuong et al. In vivo sensitivity monitoring of chloroquine for the treatment of uncomplicated vivax malaria in four bordered provinces of Thailand during 2009-2010
Veroux et al. Visceral leishmaniasis in the early post‐transplant period after kidney transplantation: clinical features and therapeutic management
Georgiadou et al. Anemia and tissue hypoxia are major determinants of malarial hypelactatemia
US20090186949A1 (en) Method for Treating Endothelial and Epithelial Cell Disorders by Administering High Molecular Weight PEG-Like Compounds
Nyawira Maranga et al. IL‐6 is upregulated in late‐stage disease in monkeys experimentally infected with Trypanosoma brucei rhodesiense
Fernández et al. Uncomplicated Plasmodium vivax malaria: mapping the proteome from circulating platelets
US20220404378A1 (en) Methods and compositions for determining oxpl-associated diseases and disorders
WO2019053117A1 (en) Pct and pro-adm as markers for monitoring antibiotic treatment
US20220389074A1 (en) Compositions and uses thereof for treating, prognosing and diagnosing pulmonary hypertension
Pirotte Detailed investigation of erythropoiesis and iron metabolism in the context of allogeneic hematopoietic stem cell transplantation